Get the Stockscreener App
14.01
5.40%
-0.80
Pre-market:
14.00
-0.010
-0.07%
Zymeworks Inc. stock is traded at $14.01, with a volume of 562.52K.
It is down -5.40% in the last 24 hours and up +11.46% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$14.81
Open:
$13.91
24h Volume:
562.52K
Relative Volume:
1.25
Market Cap:
$1.05B
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-9.2781
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
-5.53%
1M Performance:
+11.46%
6M Performance:
+4.55%
1Y Performance:
+19.44%
1-Day Range:
$13.80
$14.72
1-Week Range:
$13.80
$15.35
52-Week Range:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.01 | 1.12B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Detecting price anomalies in Zymeworks Inc. with AIJuly 2025 Levels & Real-Time Stock Entry Alerts - Newser
Has Zymeworks Inc. found a price floorStop Loss & Low Drawdown Investment Strategies - Newser
Why Zymeworks Inc. stock attracts strong analyst attention2025 Growth vs Value & Long-Term Growth Plans - Newser
Risk adjusted return profile for Zymeworks Inc. analyzedEarnings Overview Report & Accurate Technical Buy Alerts - Newser
Tema Etfs LLC Makes New $393,000 Investment in Zymeworks Inc. $ZYME - MarketBeat
Nuveen LLC Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks Inc. $ZYME Shares Sold by Walleye Capital LLC - MarketBeat
Zymeworks Inc. $ZYME Shares Bought by AlphaQuest LLC - MarketBeat
Zymeworks Inc. $ZYME Shares Sold by Vanguard Group Inc. - MarketBeat
Is Zymeworks Inc. forming a breakout patternQuarterly Risk Review & Stepwise Trade Execution Plans - خودرو بانک
Zymeworks’ Pipeline Resilience Amid ZW171 Setback: Strategic Reallocation and ADC Innovation Drive Long-Term Value - AInvest
Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On (NASDAQ:ZYME) - Seeking Alpha
Sentiment analysis tools applied to Zymeworks Inc.Stop Loss & Capital Efficient Trade Techniques - Newser
Is Zymeworks Inc. stock a good pick for beginnersJuly 2025 Pullbacks & Free Expert Approved Momentum Trade Ideas - خودرو بانک
What machine learning models say about Zymeworks Inc.2025 Fundamental Recap & Community Driven Trade Alerts - Newser
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit - uk.finance.yahoo.com
Zymeworks Inc. shares fall 3.31% intraday after discontinuing clinical development of ZW171. - AInvest
What Fibonacci levels say about Zymeworks Inc. reboundLong Setup & Risk Controlled Daily Trade Plans - Newser
Zymeworks down after dropping anticancer agent (ZYME:NASDAQ) - Seeking Alpha
Zymeworks stock falls after discontinuing cancer drug development - Investing.com
Zymeworks Discontinues ZW171 Development Amidst Strategic Pipeline Focus - TipRanks
Zymeworks halts development of cancer drug after trial setback - MarketScreener
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager - The Manila Times
Clinical Development Ends: Zymeworks' Cancer Drug ZW171 Shows Concerning Safety Profile in Phase 1 - Stock Titan
Heatmap analysis for Zymeworks Inc. and competitorsQuarterly Profit Report & Capital Efficiency Focused Strategies - Newser
Wellington Management Group LLP Decreases Stock Holdings in Zymeworks Inc. $ZYME - MarketBeat
Real time pattern detection on Zymeworks Inc. stockEarnings Overview Report & Comprehensive Market Scan Insights - Newser
Will Zymeworks Inc. bounce back from current supportProduct Launch & Safe Entry Trade Signal Reports - Newser
What is the Moat Score of Zymeworks Inc.July 2025 Levels & Fast Gain Swing Trade Alerts - خودرو بانک
Predicting Zymeworks Inc. trend using moving averages2025 Price Action Summary & Expert Curated Trade Ideas - Newser
Evaluating Zymeworks Inc. with trendline analysisWeekly Investment Summary & Daily Volume Surge Trade Alerts - Newser
Volume Report: Will Zymeworks Inc. be affected by tariffsJuly 2025 PreEarnings & Community Consensus Picks - خودرو بانک
What is Zymeworks Inc.’s TAM (Total Addressable Market)July 2025 Price Swings & Precise Buy Zone Identification - خودرو بانک
Can Zymeworks Inc. be recession proof2025 Major Catalysts & Real-Time Volume Triggers - خودرو بانک
Will Zymeworks Inc. benefit from green energy policies2025 Geopolitical Influence & AI Based Trade Execution Alerts - خودرو بانک
What’s the fair value of Zymeworks Inc. stockEarnings Beat & Verified Chart Pattern Signals - خودرو بانک
Sector ETF performance correlation with Zymeworks Inc.Market Growth Review & Weekly Market Pulse Alerts - Newser
Multi factor analysis applied to Zymeworks Inc.July 2025 Update & Fast Exit Strategy with Risk Control - Newser
Order flow analysis tools used on Zymeworks Inc.2025 Top Gainers & Weekly High Return Stock Forecasts - Newser
Zymeworks Inc. stock trend forecastPortfolio Risk Summary & Real-Time Market Sentiment Reports - Newser
What candlestick patterns are forming on Zymeworks Inc.Portfolio Risk Summary & Long-Term Growth Plans - Newser
Can momentum traders help lift Zymeworks Inc.2025 Momentum Check & High Win Rate Trade Alerts - Newser
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):